A Joel Papowitz, MD
Pulmonary Disease · Norwalk, CTNPI 1477675098
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $676 of the $881 with a category attached, or 76.7%. 10 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 25.5% of the total. 2025 is the largest year on record at $530, more than ten times the $16 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in CT, where the typical reported total is $1,017.
Across 32 payments — averaging $27.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$225
- Jazz Pharmaceuticals Inc.$207
- Avadel CNS Pharmaceuticals, LLC$168
- Inspire Medical Systems, Inc.$92
- Harmony Biosciences LLC$75
- Merck$54
- plus $61 from 4 others
What the payments were for
- Consulting fees$15017%
- Food & beverage$67677%
- Education$556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $225 |
| Jazz Pharmaceuticals Inc. | 3 | $207 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $168 |
| Inspire Medical Systems, Inc. | 4 | $92 |
| Harmony Biosciences LLC | 2 | $75 |
| Merck | 3 | $54 |
| Optinose US, Inc. | 1 | $17 |
| Medline Industries LP | 1 | $16 |
| Organogenesis Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$881 in reported general payments places this provider in the 45th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 13 | $734 |
| Clonazepam | 16 | $214 |
| Trazodone Hcl | 12 | $12 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Norwalk
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.